Top

Osteoporosis International

Published in:

01-02-2010 | Original Article

Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study

Authors: E. Gineyts, F. Munoz, C. Bertholon, E. Sornay-Rendu, R. Chapurlat

Published in: Osteoporosis International | Issue 2/2010

Abstract

Summary

The aim of the study was to investigate prospectively whether the levels of urinary pentosidine could predict fractures in postmenopausal women from the OFELY cohort. The results of the study suggest that urine pentosidine concentration is not an independent risk factor for fractures in postmenopausal women from a French cohort.

Introduction

Pentosidine has been described as an independent risk factor for hip and vertebral fracture in postmenopausal Japanese women. We investigated the prediction of urinary pentosidine on all fragility fracture risk in healthy untreated postmenopausal women from the OFELY cohort.

Methods

Urinary pentosidine was assessed at baseline in 396 healthy untreated postmenopausal women aged 63.3 ± 8.4 years from the OFELY cohort using high-performance liquid chromatography method. Incident clinical fractures were recorded during annual follow-up and confirmed by radiographs, and vertebral fractures were assessed on radiographs performed every 4 years. Multivariate Cox’s regression analysis was used to calculate the risk of urinary pentosidine levels after adjustment for age, prevalent fractures, and total hip bone mineral density (BMD).

Results

During a mean follow-up of 10 years, 88 of the 396 postmenopausal women have undergone incident vertebral (n = 28) and peripheral (n = 60) fractures. Fracture risk was higher in postmenopausal women with pentosidine in the highest quartile (p = 0.02), but it did not remain significant after adjustment for age, BMD, and prevalent fracture.

Conclusions

Urine pentosidine concentration is not an independent risk factor of osteoporotic fracture in healthy postmenopausal women from the OFELY cohort.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef

Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822CrossRefPubMed

Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202CrossRefPubMed

Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819CrossRefPubMed

Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32:78–85CrossRefPubMed

Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 332:767–773CrossRefPubMed

Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382CrossRefPubMed

Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Eng J Med 354:2250–2261CrossRef

Chavassieux P, Seeman E, Delmas PD (2007) Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocrine Rev 28:151–164CrossRef

10.

Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedCrossRef

11.

Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536CrossRefPubMed

12.

Vergnaud P, Garnero P, Meunier PJ, Bréart G, Kamihagi K, Delmas PD (1997) Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 82:719–724CrossRefPubMed

13.

Garnero P, Sornay-Rendu E, Delmas PD (2000) Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 355:898–899CrossRefPubMed

14.

Chapurlat RD, Garnero P, Bréart G, Meunier PJ, Delmas PD (2000) Serum estradiol and sex hormone-binding globulin and the risk of hip fracture in elderly women: the EPIDOS study. J Bone Miner Res 15:1835–1841CrossRefPubMed

15.

Sell DR, Monnier VM (1989) Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. J Biol Chem 264:21597–21602PubMed

16.

Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463–2469CrossRefPubMed

17.

Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, Bayliss MT, Bijlsma JW, Lafeber FP, Tekoppele JM (2000) Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 350:381–387CrossRefPubMed

18.

Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A (2005) Advanced glycation end products and bone loss during aging. Ann NY Acad Sci 1043:710–717CrossRefPubMed

19.

Saito M, Marumo K, Fujii K, Ishioka N (1997) Single-column high-performance liquid chromatographic-fluorescence detection of immature, mature, and senescent cross-links of collagen. Anal Biochem 253:26–32CrossRefPubMed

20.

Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD (2006) Extracellular posttranslational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38:300–309CrossRefPubMed

21.

Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML (2006) Contribution of the advanced glycation endproduct pentosidine and of maturation of type I collagen to compressive biomechanica properties of human lumbar vertebrae. Bone 39:1073–1079CrossRefPubMed

22.

Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17:986–995CrossRefPubMed

23.

Yoshihara K, Nakamura K, Kanai M, Nagayama Y, Takahashi S, Saito N, Nagata M (1998) Determination of urinary and serum pentosidine and its application to elder patients. Biol Pharm Bull 21:1005–1008PubMed

24.

Takahashi M, Oikawa M, Nagano A (2000) Effect of age and menopause on serum concentrations of pentosidine, an advanced glycation end product. J Gerontol A Biol Sci Med Sci 55:137–140

25.

Hein G, Wiegand R, Lehmann G, Stein G, Franke S (2003) Advanced glycation end-products pentosidine and Nε-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42:1242–1246CrossRefPubMed

26.

Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T (2008) Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 26:93–100CrossRefPubMed

27.

Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349PubMed

28.

Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD (1997) Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 12:683–690CrossRefPubMed

29.

Viguet-Carrin S, Gineyts E, Bertholon C, Delmas PD (2009) Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single-column high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 877:1–7CrossRefPubMed

30.

Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148

31.

Sell DR, Nagaraj RH, Grandhee SK, Odetti P, Lapolla A, Fogarty J, Monnier VM (1991) Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev 7:239–251CrossRefPubMed

32.

Odetti P, Fogarty J, Sell DR, Monnier VM (1992) Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153–159CrossRefPubMed

33.

Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244:45–49CrossRefPubMed

34.

Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, Van Ypersele de Strihou C, Kurokawa K (1998) Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 9:1681–1688PubMed

35.

Kitauchi T, Yoshida K, Yoneda T, Saka T, Yoshikawa M, Ozono S, Hirao Y (2004) Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin Exp Nephrol 8:48–53CrossRefPubMed

36.

Sanaka T, Funaki T, Tanaka T, Hoshi S, Niwayama J, Taitoh T, Nishimura H, Higuchi C (2002) Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 91:64–73CrossRefPubMed

37.

Garnero P, Mulleman D, Munoz F, Sornay-Rendu E, Delmas PD (2003) Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study. J Bone Miner Res 18:1789–1794CrossRefPubMed

38.

Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, Nevitt MC, Cummings SR (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res 18:1947–1154CrossRefPubMed

39.

Taylor BC, Schreiner PJ, Stone KL, Fink HA, Cummings SR, Nevitt MC, Bowman PJ, Ensrud KE (2004) Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 52:1479–1486CrossRefPubMed

40.

Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, Cauley JA, Ensrud KE, Hochberg MC, Cummings SR (2007) Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 167:155–160CrossRefPubMed

41.

Cefalu WT, Bell-Farrow AD, Wang ZQ, Sonntag WE, Fu MX, Baynes JW, Thorpe SR (1995) Caloric restriction decreases age-dependent accumulation of the glycoxidation products, N epsilon-(carboxymethyl) lysine and pentosidine, in rat skin collagen. J Gerontol A Biol Sci Med Sci 50:B337–B341

42.

Sell DR, Monnier VM (1997) Age-related association of tail tendon break time with tissue pentosidine in DBA/2 vs C57BL/6 mice: the effect of dietary restriction. J Gerontol A Biol Sci Med Sci 52:B277–B284PubMed

43.

Förster A, Kühne Y, Henle T (2005) Studies on absorption and elimination of dietary maillard reaction products. Ann N Y Acad Sci 1043:474–481CrossRefPubMed

44.

Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, Ypersele de Strihou C van, Maeda K (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198–1206PubMed

45.

Miyata T, Ueda Y, Horie K, Nangaku M, Tanaka S, Ypersele de Strihou C van, Kurokawa K (1998) Renal catabolism of advanced glycation end products: the fate of pentosidine. Kidney Int 53:416–422CrossRefPubMed

Title: Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study
Authors: E. Gineyts
F. Munoz
C. Bertholon
E. Sornay-Rendu
R. Chapurlat
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0939-5

At a glance: The STEP trials

Springer Medicine

Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

A multicenter survey on profile of care for hip fracture: predictors of mortality and disability

Direct-to-participant feedback and awareness of bone mineral density testing results in a population-based sample of mid-aged Canadians

Osteoporosis and gait and balance disturbances in older sarcopenic obese New Zealanders

Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus

Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures

Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur